PaxVax

February 17, 2020

Solving the mystery of Vifor’s new voucher

August 22, 2019

Astra could use a voucher to cement roxadustat’s head start

Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.

August 31, 2018

Working for the government proves extremely profitable for Emergent

With its latest acquisition Emergent Biosolutions is tapping into new ways to access public spending.

February 24, 2017

Snippet roundup: Cyclacel’s data dredge and Bristol’s activist investor

February 24, 2017

Snippet roundup: Cyclacel’s data dredge and Bristol’s activist investor

January 18, 2017

Faster FDA adds a positive spin to 2016's disappointing approval record

September 22, 2016

Priority review vouchers revisited